Legend Historical Cash Flow
| LEGN Stock | USD 42.69 1.75 4.27% |
Analysis of Legend Biotech cash flow over time is an excellent tool to project Legend Biotech Corp future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Begin Period Cash Flow of 826.7 M or Other Cashflows From Financing Activities of 222.1 M as it is a great indicator of Legend Biotech ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining Legend Biotech Corp latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Legend Biotech Corp is a good buy for the upcoming year.
Legend |
About Legend Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in Legend balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Legend's non-liquid assets can be easily converted into cash.
Legend Biotech Cash Flow Chart
Add Fundamental
Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Capital Expenditures
Capital Expenditures are funds used by Legend Biotech Corp to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Legend Biotech operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.Most accounts from Legend Biotech's cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Legend Biotech Corp current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Legend Biotech Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. At this time, Legend Biotech's Total Cash From Financing Activities is very stable compared to the past year. As of the 26th of November 2024, End Period Cash Flow is likely to grow to about 1.3 B, though Change To Inventory is likely to grow to (12.1 M).
Legend Biotech cash flow statement Correlations
Click cells to compare fundamentals
Legend Biotech Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Legend Biotech cash flow statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change To Inventory | (22K) | (643K) | 51K | (8.6M) | (12.7M) | (12.1M) | |
| Investments | (58.7M) | 25.6M | (195.0M) | (78.3M) | 92.8M | 97.4M | |
| Change In Cash | (126.8M) | 372.3M | 233.2M | 97.1M | 490.8M | 515.3M | |
| Net Borrowings | 14.7M | (2.6M) | (1.4M) | (2.6M) | (2.3M) | (2.2M) | |
| Free Cash Flow | (122.2M) | (272.8M) | (245.6M) | (222.3M) | (416.0M) | (395.2M) | |
| Change In Working Capital | 52.5M | (23.9M) | 140.9M | 186.3M | (71.3M) | (67.8M) | |
| Begin Period Cash Flow | 210.2M | 83.4M | 455.7M | 688.9M | 787.3M | 826.7M | |
| Total Cashflows From Investing Activities | (58.7M) | (24.2M) | (195.0M) | (77.1M) | (69.4M) | (72.9M) | |
| Other Cashflows From Financing Activities | 22.6M | 159.4M | 4.6M | 2.9M | 211.6M | 222.1M | |
| Depreciation | 5.3M | 9.9M | 13.9M | 18.4M | 20.5M | 11.0M | |
| Other Non Cash Items | (4.4M) | 84.6M | 187.7M | 6.6M | 128.2M | 71.5M | |
| Capital Expenditures | 39.2M | 49.8M | 47.1M | 22.3M | 22.7M | 31.9M | |
| Total Cash From Operating Activities | (83.1M) | (223.0M) | (198.5M) | (200.0M) | (393.3M) | (373.6M) | |
| Change To Account Receivables | (3.8M) | (45M) | 24.6M | 50.3M | (99.0M) | (94.0M) | |
| Change To Operating Activities | 27.8M | 20.0M | 136.7M | 118.8M | 136.6M | 143.4M | |
| Net Income | (130.4M) | (307.6M) | (386.2M) | (445.7M) | (518.3M) | (492.3M) | |
| Total Cash From Financing Activities | 14.7M | 618.9M | 626.7M | 378.0M | 791.5M | 831.1M | |
| End Period Cash Flow | 83.4M | 455.7M | 688.9M | 786.0M | 1.3B | 1.3B | |
| Other Cashflows From Investing Activities | 50.0M | 47K | (195.0M) | (13.5M) | (12.1M) | (12.7M) | |
| Change To Netincome | (7.8M) | 92.0M | 187.7M | 34.2M | 39.3M | 55.1M | |
| Change To Liabilities | 28.5M | 4.1M | (20.4M) | 32.0M | 28.8M | 46.6M | |
| Stock Based Compensation | 1.3M | 4.8M | 20.2M | 34.3M | 47.7M | 50.1M |
Pair Trading with Legend Biotech
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Legend Biotech position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Legend Biotech will appreciate offsetting losses from the drop in the long position's value.Moving together with Legend Stock
| 0.74 | ME | 23Andme Holding | PairCorr |
| 0.89 | VALN | Valneva SE ADR | PairCorr |
| 0.71 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
Moving against Legend Stock
| 0.48 | KZR | Kezar Life Sciences | PairCorr |
| 0.46 | MDGL | Madrigal Pharmaceuticals | PairCorr |
| 0.41 | RNXT | RenovoRx | PairCorr |
| 0.4 | MLYS | Mineralys Therapeutics, | PairCorr |
| 0.36 | NXGLW | NexGel Warrant | PairCorr |
The ability to find closely correlated positions to Legend Biotech could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Legend Biotech when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Legend Biotech - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Legend Biotech Corp to buy it.
The correlation of Legend Biotech is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Legend Biotech moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Legend Biotech Corp moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Legend Biotech can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Legend Biotech Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Legend Biotech. If investors know Legend will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Legend Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.92) | Revenue Per Share 2.851 | Quarterly Revenue Growth 0.669 | Return On Assets (0.12) | Return On Equity (0.28) |
The market value of Legend Biotech Corp is measured differently than its book value, which is the value of Legend that is recorded on the company's balance sheet. Investors also form their own opinion of Legend Biotech's value that differs from its market value or its book value, called intrinsic value, which is Legend Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Legend Biotech's market value can be influenced by many factors that don't directly affect Legend Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Legend Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Legend Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Legend Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.